IRIS
VITA, GIANLUCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 7.429
NA - Nord America 6.325
AS - Asia 4.333
SA - Sud America 1.380
Continente sconosciuto - Info sul continente non disponibili 380
AF - Africa 131
OC - Oceania 11
Totale 19.989
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.157
RU - Federazione Russa 3.823
SG - Singapore 1.961
BR - Brasile 1.177
CN - Cina 1.165
IE - Irlanda 902
IT - Italia 610
SE - Svezia 603
HK - Hong Kong 384
PL - Polonia 334
DE - Germania 288
VN - Vietnam 284
FR - Francia 282
FI - Finlandia 178
GB - Regno Unito 160
IN - India 128
BD - Bangladesh 88
UA - Ucraina 83
AR - Argentina 77
CA - Canada 63
MX - Messico 56
TR - Turchia 45
IQ - Iraq 43
ZA - Sudafrica 38
ID - Indonesia 37
BE - Belgio 32
AT - Austria 30
EC - Ecuador 30
CI - Costa d'Avorio 28
JP - Giappone 28
NL - Olanda 25
CO - Colombia 24
VE - Venezuela 23
PK - Pakistan 22
MA - Marocco 19
ES - Italia 18
CL - Cile 16
KE - Kenya 15
UZ - Uzbekistan 15
LT - Lituania 14
MY - Malesia 13
PH - Filippine 13
SA - Arabia Saudita 13
CZ - Repubblica Ceca 12
AE - Emirati Arabi Uniti 11
CR - Costa Rica 11
PE - Perù 11
JO - Giordania 10
PY - Paraguay 10
TN - Tunisia 10
EU - Europa 9
JM - Giamaica 9
AZ - Azerbaigian 8
IL - Israele 8
KZ - Kazakistan 8
NP - Nepal 8
AU - Australia 7
EG - Egitto 7
HN - Honduras 7
RO - Romania 6
UY - Uruguay 6
DO - Repubblica Dominicana 5
OM - Oman 5
KW - Kuwait 4
NI - Nicaragua 4
NZ - Nuova Zelanda 4
PA - Panama 4
SK - Slovacchia (Repubblica Slovacca) 4
BO - Bolivia 3
BY - Bielorussia 3
CY - Cipro 3
GY - Guiana 3
HU - Ungheria 3
IR - Iran 3
KR - Corea 3
LB - Libano 3
TH - Thailandia 3
TT - Trinidad e Tobago 3
XK - ???statistics.table.value.countryCode.XK??? 3
AL - Albania 2
AO - Angola 2
GA - Gabon 2
GT - Guatemala 2
KG - Kirghizistan 2
LK - Sri Lanka 2
MD - Moldavia 2
PS - Palestinian Territory 2
PT - Portogallo 2
RS - Serbia 2
SN - Senegal 2
SV - El Salvador 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BH - Bahrain 1
BN - Brunei Darussalam 1
CG - Congo 1
CH - Svizzera 1
DK - Danimarca 1
Totale 19.598
Salva come PNG Salva come JPEG
Città #
Moscow 1.121
Ashburn 975
Dublin 901
Singapore 814
Chandler 615
Dallas 590
Beijing 429
Hong Kong 384
Nyköping 377
Warsaw 322
San Jose 300
Council Bluffs 249
Jacksonville 238
The Dalles 221
Princeton 175
Messina 147
Medford 140
Lauterbourg 137
Ann Arbor 135
Los Angeles 131
Cambridge 114
Ho Chi Minh City 100
New York 98
Munich 92
Des Moines 91
São Paulo 83
Buffalo 66
Boardman 63
Dearborn 62
Lancaster 59
Bremen 58
Tianjin 58
Shenyang 57
Pune 53
San Mateo 49
Turku 47
Frankfurt am Main 46
Orem 46
Hanoi 45
Wilmington 44
Jinan 42
Rio de Janeiro 42
Redondo Beach 41
Rome 41
Houston 37
Santa Clara 37
Atlanta 32
Belo Horizonte 32
Nanjing 31
Brussels 30
Abidjan 28
Guangzhou 28
Milan 26
Tokyo 25
Brooklyn 24
Chennai 24
Porto Alegre 24
Hebei 23
Curitiba 22
Hangzhou 22
Helsinki 22
Ningbo 22
Brasília 21
Zhengzhou 21
Dong Ket 20
Baghdad 19
Montreal 18
Toronto 18
Amsterdam 17
London 16
Johannesburg 15
Phoenix 15
Seattle 15
Shanghai 15
Stockholm 15
Woodbridge 15
Catania 14
Jakarta 14
Nuremberg 14
Salvador 14
Tashkent 14
Vienna 14
Changsha 13
Denver 13
Manchester 13
Mexico City 13
Palo Del Colle 13
Taizhou 13
Chicago 12
Dhaka 12
Guarulhos 12
Nanchang 12
Quito 12
San Francisco 12
Campinas 11
Haikou 11
Hyderabad 11
Istanbul 11
Juiz de Fora 11
Nairobi 11
Totale 10.927
Salva come PNG Salva come JPEG
Nome #
6MWT performance correlates with peripheral neuropathy but not with cardiac involvement in patients with hereditary transthyretin amyloidosis (hATTR) 336
Psychosocial impact of presymptomatic genetic testing for amyloidotic polyneuropathy 288
Psychosocial impact of presymptomatic genetic testing for amyloidotic polyneuropathy 259
A Phase 1/2 Study of Flavocoxid, an Oral NF-κB Inhibitor, in Duchenne Muscular Dystrophy 256
Clinical and pathological features of focal myositis 251
Integrated care of muscular dystrophies in Italy. Part 1. Pharmacological treatment and rehabilitative interventions 245
Integrated care of muscular dystrophies in Italy. Part 2. Psychological treatments, social and welfare support, and financial costs 241
Circulating miRNAs expression as potential biomarkers of mild traumatic brain injury 221
Circulating microRNAs Profile in Patients With Transthyretin Variant Amyloidosis 218
24 month longitudinal data in ambulant boys with Duchenne muscular dystrophy. 211
Anabolic treatment with RHPTH of duchenne muscular dystrophy related osteoporosis: a case report 202
Health-related quality of life and functional changes in DMD: A 12-month longitudinal cohort study 201
Which are the factors influencing NIV adaptation and tolerance in ALS patients? 201
Dolori muscolari, deficit di forza e/o disturbi sensitivi 200
microRNA-10 and -221 modulate differential expression of Hippo signaling pathway in human astroglial tumors 200
Modulation of neuronal nitric oxide synthase and apoptosis by the isoflavone genistein in Mdx mice 197
Hippo signaling pathway is altered in Duchenne muscular dystrophy 192
Effect of exercise on telomere length and telomere proteins expression in mdx mice 192
Nusinersen versus sham control in later-onset spinal muscular atrophy 192
Autonomic nervous system involvement in spinal muscular atrophy. 191
Emergenze respiratorie nelle malattie neurologiche 185
Parenteral nutrition improves nutritional status, autonomic symptoms and quality of life in transthyretin amyloid polyneuropathy 184
Benefits of glucocorticoids in non-ambulant boys/men with Duchenne muscular dystrophy: A multicentric longitudinal study using the Performance of Upper Limb test 182
Intrathecal administration of Nusinersen in type 1 SMA: successful psychological program in a single Italian center 179
ANT1 is reduced in sporadic inclusion body myositis. 179
Pilot study of flavocoxid in ambulant DMD patients. 174
6 Minute Walk Test in Duchenne MD Patients with Different Mutations: 12 Month Changes 173
Pilot study of serial casting in muscular dystrophy patients. 171
Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 1: peripheral neuropathies 171
ANT1 expression and RAGE-NF-kB pathway in sporadic inclusion body myositis. 170
Pilot study of serial casting of ankles in muscular dystrophy patients. 168
Neuropsychological patter in centronuclear myopathy due to DNM2 gene mutations. 168
Modulation of neural nitric oxide synthase by the isoflavone genistein promotes muscle regeneration in mdx mice 167
Parenteral nutrition improves nutritional status, autonomic symptoms and qol in patients with TTR-FAP 164
Predictors of adaptation to non-invasive ventilation in amyotrophic lateral sclerosis 161
Bone health in Duchenne muscular dystrophy: clinical and biochemical correlates 160
Psycological status and emotional burden in amyotrophic lateral sclerosis caregivers: the role of metacognitive processes. 159
Impaired myocardial deformation revealing subclinical left ventricular dysfunction in children with Duchenne dystrophy: a speckle tracking echocardiography study 158
Impaired myocardial strain in early stage of Duchenne muscular dystrophy: its relation with age and motor performance 158
Predictors of adaptation to non-invasive ventilation in neuromuscular disorders. 157
Outcome measures in Duchenne muscular dystrophy: validation of the Pediatric Quality of Life InventoryTM Neuromuscular Module in the Italian population and correlation with other functional assessments. 157
Dolori muscolari, deficit di forza e/o disturbi sensitivi 156
Psychosocial impact of sport activity in neuromuscular disorders 156
The 24-month PUL changes and steroids correlation. 155
Novel outcome measures for Charcot-Marie-Tooth disease: Validation and reliability of the 6-min walk test and StepWatch™ Activity Monitor and identification of the walking features related to higher quality of life 154
Activation of NF-kappaB pathway in Duchenne muscular dystrophy: relation to age 153
Pilot study of flavocoxid in ambulant DMD patients. 152
Severe rhabdomyolysis in a patient with “Heat Stroke” 152
Pilot study of flavocoxid in ambulant DMD patients. 152
Burden, professional support, and social network in families of children and young adults with muscular dystrophies 150
BONE INVOLVEMENT IN DUCHENNE MUSCULAR DYSTROPHY 150
Telomere shortening is associated to TRF1 and PARP1 overexpression in Duchenne muscular dystrophy 150
Burden, social network and professional support in the families of patients with muscular dystrophies: results from the GUP10002 study. 148
ANT1 expression and RAGE-NF-kB pathway in sporadic inclusion body myositis 148
Clinical variability in spinal muscular atrophy type III 148
First report of a family with a DMD out of frame exon 2 deletion associated with asymptomatic phenotypes. 146
Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes 145
Teriparatide (rhPTH 1-34) in Duchenne Muscular Dystrophy related osteoporosis: a case report. 145
Genetic Modifiers of Duchenne Muscular Dystrophy and Dilated Cardiomyopathy 144
Sport activity in Charcot-Marie-Tooth disease: A case study of a Paralympic swimmer 144
Effects of teriparatide on bone mineral density and quality of life in Duchenne muscular dystrophy related osteoporosis: a case report 144
Impaired rotational mechanics and strain revealing subclinical left ventricular dysfunction in children with Duchenne muscular dystrophy: a skeckle tracking study. 144
Cardiac function in types II and III spinal muscular atrophy: should we change standards of care? 144
Telomere shortening and telomere-associated proteins in Duchenne muscular dystrophy. 143
Practical approach to respiratory emergencies in neurological diseases 143
Teriparatide (rhPTH 1-34) in Duchenne Muscular Dystrophy related osteoporosis: a case report 139
First report of a family with a DMD out of frame exon 2 deletion associated with asymptomatic phenotypes. 138
Timed rise from floor as a predictor of disease progression in Duchenne muscular dystrophy: An observational study 137
Teriparatide (rhPTH) treatment in Duchenne Muscular Dystrophy, a case report. 137
Espressione di ANT1 e attivazione della via RAGE-NF-kB nella miosite a corpi inclusi. 136
Selective short-term verbal memory involvement in two siblings carrying centronuclear myopathy due to DNM2 gene mutations 136
Amyloid myopathy presenting with rhabdomyolysis. 134
Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 2: diseases of motor neuron and skeletal muscle 134
Impaired rotational mechanics and strain revealing subclinical left ventricular dysfunction in children with neuromuscolar disorders: a speckle tracking study 132
6 min walking test 12 month changes in DMD: Correlation with genotype. 132
Implication of SIRT1 and its downstream pathways in dystrophic process. 132
Respiratory Emergencies in Neurological Diseases 132
study of flavocoxid in ambulant DMD patients. 131
Histological effects of givinostat in boys with Duchenne muscular dystrophy 130
Muscle Fat-Fraction and Mapping in Duchenne Muscular Dystrophy: Evaluation of Disease Distribution and Correlation with Clinical Assessments: A preliminary experience. 129
Bone quality in Duchenne muscular dystrophy 128
Telomere shortening and telomere associated proteins in exercised wild type and mdx mice. 123
MYH7-related myopathies: Clinical, histopathological and imaging findings in a cohort of Italian patients 123
Pilot study of flavocoxid in ambulant DMD patients. 123
The 6 minute walk test and performance of upper limb in ambulant duchenne muscular dystrophy boys 122
Dual-echo dual flip angle gradient-echo MRI technique for quantification of muscle fat fraction in Duchenne muscular dystrophy: a new valuable outcome measure. 121
The soy isoflavone genistein blunts nuclear factor kappa-B, MAPKs and TNF-α activation and ameliorates muscle function and morphology in mdx mice. 120
Flavocoxid counteracts muscle necrosis and improves functional properties in mdx mice: a comparison study with methylprednisolone 118
Reliability of the Performance of Upper Limb assessment in Duchenne muscular dystrophy 117
Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy 117
Role of calcineurin/NFAT on muscle regeneration in dystrophic process. 116
Psychological and practical difficulties among parents and healthy siblings of children with Duchenne vs. Becker muscular dystrophy: an Italian comparative study 114
Miopatia prossimale in paziente con sindrome di Williams 110
Pilot study of flavocoxid in ambulant DMD patients. 104
Psychosocial impact of presymptomatic genetic testing for transthyretin amyloidotic polyneuropathy 103
The Genetic Landscape of Dystrophin Mutations in Italy: A Nationwide Study 103
Safety and effectiveness of ataluren: comparison of results from the STRIDE Registry and CINRG DMD Natural History Study 103
The first report of a patient carrying an out-of-frame exon2 deletion in the dystrophin gene and showing a very unusual phenotype. 102
Telomere length in exercised wild type and mdx mice. 101
L'inibizione dei pathway del fattore nucleare-kappaB, delle MAP chinasi e di COX/5-LOX mediante trattamento con flavocoxid migliora la funzione e la morfologia muscolare nel topo mdx: uno studio comparativo con il metilprednisolone 100
Totale 15.882
Salva come PNG Salva come JPEG
Categoria #
all - tutte 67.538
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 67.538
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022939 0 97 4 64 48 6 94 37 33 91 88 377
2022/20232.391 195 227 125 158 202 197 18 114 1.081 6 57 11
2023/2024724 31 114 35 82 52 174 35 41 5 32 25 98
2024/20253.384 61 45 39 190 91 84 76 640 721 188 537 712
2025/20269.278 471 615 701 677 724 1.858 1.112 1.122 1.202 420 188 188
2026/2027735 195 540 0 0 0 0 0 0 0 0 0 0
Totale 19.989